Current and future treatments of autoimmune hepatitis

References

• Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q. J. Med.40, 159–185 (1971).
   PubMedGoogle Scholar
• Soloway RD, Summerskill WHJ, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology63, 820–833 (1972).
   PubMed Web of Science ®Google Scholar
• Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet1, 735–737 (1973).
   PubMed Web of Science ®Google Scholar
• Floreani A, Niro G, Rosa Rizzotto E et al. Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment. Pharmacol. Ther.24(7), 1051–1057 (2006).
   PubMed Web of Science ®Google Scholar
• Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J. Gastroenterol. Hepatol.23, 1410–1414 (2008).
   PubMed Web of Science ®Google Scholar
• Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology110, 848–857 (1996).
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J. Hepatol.18, 15–23 (1993).
   PubMed Web of Science ®Google Scholar
• Dufour J-F, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann. Intern. Med.127, 981–985 (1997).
   PubMed Web of Science ®Google Scholar
• Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J. Clin. Gastroenterol.32, 428–430 (2001).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology39, 1631–1638 (2004).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J. Hepatol.40, 644–650 (2004).
   Web of Science ®Google Scholar
• Mohamadnejad M, Malekzadeh R, Nasseri-Maghaddam S et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig. Dis. Sci.50, 547–551 (2005).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology4, 622–627 (1984).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin. Drug Saf.7(3), 319–333 (2008).
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end stage liver disease. Hepatology46, 1138–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology78, 518–523 (1980).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N. Engl. J. Med.304, 5–9 (1981).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology35, 890–897 (2002).
   PubMed Web of Science ®Google Scholar
• Hegarty JE, Nouri-Aria KT, Portmann B, Eddleston ALWF, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology3, 685–689 (1983).
   PubMed Web of Science ®Google Scholar
• Stellon AJ, Keating JJ, Johnson PJ, MacFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology8, 781–784 (1988).
   PubMed Web of Science ®Google Scholar
• Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N. Engl. J. Med.333, 958–963 (1995).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J. Hepatol. DOI: 10.1016/j.jhep.2009.02.026 (2009) (Epub ahead of print).
   Google Scholar
• Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology92, 215–219 (1987).
   PubMed Web of Science ®Google Scholar
• Montano-Loza A, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int.27, 507–515 (2007).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Progress in the diagnosis and treatment of autoimmune hepatitis. Minerva Med.99(6), 549–568 (2008).
   PubMedGoogle Scholar
• Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and non-Caucasians. Sem. Liver Dis. (In Press) (2009).
   Google Scholar
• Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am. J. Gastroenterol.103, 1944–1951 (2008).
   PubMed Web of Science ®Google Scholar
• Yeoman AD, Al-Chalabi T, Karani JB et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology48, 863–870 (2008).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl.8, 505–513 (2002).
   PubMed Web of Science ®Google Scholar
• Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin. Liver Dis.6, 825–850 (2002).
   PubMedGoogle Scholar
• Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr. Drug Targets Inflamm. Allergy1, 317–326 (2002).
   PubMedGoogle Scholar
• Czaja AJ. Treatment of autoimmune hepatitis. Sem. Liver Dis.22, 365–377 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol. Dietol.53, 43–78 (2007).
   PubMedGoogle Scholar
• Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J. Gastroenterol. (In Press) (2009).
   Google Scholar
• Czaja AJ, Bianchi FB, Carpenter HA et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology41, 207–215 (2005).
   PubMed Web of Science ®Google Scholar
• Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am. J. Dig. Dis.22, 973–980 (1977).
   PubMedGoogle Scholar
• Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum. Pathol.3, 183–198 (1972).
   PubMed Web of Science ®Google Scholar
• Cooksley WGE, Bradbear RA, Robinson W et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology6, 345–348 (1986).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HBsAg negative chronic active hepatitis. J. Hepatol.14, 88–93 (1992).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Magrin S, Fabiano C et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig. Dis. Sci.40, 33–40 (1995).
   PubMed Web of Science ®Google Scholar
• Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology42, 53–62 (2005).
   PubMed Web of Science ®Google Scholar
• Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am. J. Surg. Path.19, 699–708 (1995).
   PubMed Web of Science ®Google Scholar
• Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology87, 1222–1227 (1984).
   PubMed Web of Science ®Google Scholar
• Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J. Clin. Gastroenterol.35, 75–81 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. DOI: 10.1111/j.1478-3231.2008.01904.x (2008) (Epub ahead of print).
   Google Scholar
• Manns MP, Bahr MJ, Woynarowski M et al. Budesonide 3 mg TID is superior to prednisolone in combination with azathioprine in the treatment of autoimmune hepatitis (abstract). J. Hepatol.48(Suppl. 2), S369 (2008).
   PubMed Web of Science ®Google Scholar
• Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J. Clin. Gastroenterol.6, 331–335 (1984).
   PubMed Web of Science ®Google Scholar
• Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut16, 876–883 (1975).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology36, 479–497 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin. Liver Dis.6, 799–824 (2002).
   PubMedGoogle Scholar
• Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nature Clin. Pract. Gastroenterol. Hepatol.4, 202–214 (2007).
   PubMedGoogle Scholar
• Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z. Gastroenterol.39, 339–341 (2001).
   PubMed Web of Science ®Google Scholar
• Kanzler S, Gerken G, Lohr H, Galle PR, Meyer zum Buschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J. Hepatol.34, 354–355 (2001).
   PubMed Web of Science ®Google Scholar
• Montano-Loza A, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am. J. Gastroenterol.102, 1005–1012 (2007).
   PubMed Web of Science ®Google Scholar
• Schalm SW, Summerskill WHJ, Go VLW. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology72, 910–913 (1977).
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol.109, 16–22 (2000).
   PubMed Web of Science ®Google Scholar
• Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod. Asp. Immunobiol.2, 78–82 (2001).
   Google Scholar
• Chan GLC, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol.30, 358–363 (1990).
   PubMed Web of Science ®Google Scholar
• Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol.43, 329–339 (1992).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am. J. Gastroenterol.91, 423–433 (1996).
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab. Dispos.29, 601–605 (2001).
   PubMed Web of Science ®Google Scholar
• Thomas CW, Myhre GM, Tschumper R et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther.312, 537–545 (2005).
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest.111, 1133–1145 (2003).
   PubMed Web of Science ®Google Scholar
• Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev. Gastroenterol. Hepatol.2, 23–34 (2008).
   PubMedGoogle Scholar
• Lewis GP, Jusko WJ, Burke CW, Graves L. Prednisone side-effects and serum protein levels: a collaborative study. Lancet2, 778–781 (1971).
   PubMed Web of Science ®Google Scholar
• Uribe M, Go VLW. Corticosteroid pharmacokinetics in liver disease. Clin. Pharmacokinet.4, 233–240 (1979).
   PubMed Web of Science ®Google Scholar
• Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch. Dermatol.131, 193–197 (1995).
   PubMed Web of Science ®Google Scholar
• Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther.62, 60–73 (1997).
   PubMed Web of Science ®Google Scholar
• Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med.126, 608–614 (1997).
   PubMed Web of Science ®Google Scholar
• Alves S, Prata MJ, Ferreira F, Amorim A. Screening of thiopurine methyl S-transferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum. Mutat.15, 246–253 (2000).
   PubMed Web of Science ®Google Scholar
• Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med.129, 716–718 (1998).
   PubMed Web of Science ®Google Scholar
• Cuffari C, Dassopoulis T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol.2, 410–417 (2004).
   PubMed Web of Science ®Google Scholar
• McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood85, 1897–1902 (1995).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig. Dis. Sci.51, 968–975 (2006).
   PubMed Web of Science ®Google Scholar
• Bacon BR, Treuhaft WH, Goodman AM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective tissue diseases. Arch. Intern. Med.141, 223–226 (1981).
   PubMed Web of Science ®Google Scholar
• Maddocks JL, Lennard L, Amess J, Amor R, Meyrick TR. Azathioprine and severe bone marrow depression. Lancet1, 156 (1986).
   PubMed Web of Science ®Google Scholar
• Ben Ari Ziv, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J. Hepatol.23, 351–354 (1995).
   PubMed Web of Science ®Google Scholar
• Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J. Hepatol.7, 441–447 (2002).
   Google Scholar
• Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J. Hepatol.45, 584–591 (2006).
   PubMed Web of Science ®Google Scholar
• de Boer NKH, De Graaf P, Wilhelm AJ, Mulder CJJ, Van Bodegraven AA. On the limitation of 6-thioguaninenucleotide monitoring during tioguanine treatment. Aliment. Pharmacol. Ther.22, 447–451 (2005).
   PubMed Web of Science ®Google Scholar
• Lowry PW, Franklin CL, Weaver AL et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut40, 665–670 (2001).
   Web of Science ®Google Scholar
• Stellon AJ, Davies A, Compston J, Williams R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology89, 1078–1083 (1985).
   PubMed Web of Science ®Google Scholar
• Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin. Liver Dis.9, 747–766 (2005).
   PubMedGoogle Scholar
• Sanchez AJ, Aranda-Michel J. Liver disease and osteoporosis. Nutr. Clin. Pract.21, 273–278 (2006).
   PubMedGoogle Scholar
• Collier J. Bone disorders in chronic liver disease. Hepatology46, 1271–1278 (2007).
   PubMed Web of Science ®Google Scholar
• Worns MA, Teufel A, Kanzler S et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am. J. Gastroenterol.103, 138–146 (2008).
   PubMed Web of Science ®Google Scholar
• Bellot P, Garcia-Pagan JC, Abraldes JG, Bosch J. Primary prophylaxis of esophageal bleeding in cirrhosis. Gastroenterol. Clin. Biol.32, 532–540 (2008).
   PubMedGoogle Scholar
• Czaja AJ, Wolf AM, Summerskill WHJ. Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. Gastroenterology77, 629–633 (1979).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig. Dis. Sci.43, 2149–2155 (1998).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology132, 2557–2576 (2007).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology134, 1752–1763 (2008).
   PubMed Web of Science ®Google Scholar
• Miyake Y, Iwasaki Y, Terada R et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J. Hepatol.43, 951–957 (2005).
   PubMed Web of Science ®Google Scholar
• Verma S, Gunuwan B, Mendler M et al. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am. J. Gastroenterol.99, 1510–1516 (2004).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology43, 532–538 (2006).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology105, 1502–1507 (1993).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Strettell MDJ, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology25, 317–323 (1997).
   PubMed Web of Science ®Google Scholar
• Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology15, 215–221 (1992).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology80, 687–692 (1981).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int.23, 116–123 (2003).
   PubMed Web of Science ®Google Scholar
• Luth S, Herkel J, Kanzler S et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J. Clin. Gastroenterol.42, 926–930 (2008).
   PubMed Web of Science ®Google Scholar
• Runyon BA. Exquisite sensitivity to small decrements in corticosteroid dose in autoimmune chronic active hepatitis. J. Clin. Gastroenterol.9, 541–542 (1987).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology11, 1044–1049 (1990).
   PubMed Web of Science ®Google Scholar
• Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int.25, 734–739 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Chalabi T, Underhill JA, Portmann BC et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin. Gastroenterol. Hepatol.6, 1389–1395 (2008).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J. Clin. Gastroenterol.39, 819–825 (2005).
   PubMed Web of Science ®Google Scholar
• Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann. Clin. Res.8, 221–227 (1976).
   PubMedGoogle Scholar
• Schramm C, Kanzler S, Meyer zum Buschenfelde K-H, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am. J. Gastroenterol.96, 1587–1591 (2001).
   PubMed Web of Science ®Google Scholar
• Verslype C, George C, Buchel E, Nevens F, Van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment. Pharmacol. Ther.21, 695–699 (2005).
   PubMed Web of Science ®Google Scholar
• Granito A, Muratori L, Pappas G et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment. Pharmacol. Ther.21, 1273–1277 (2005).
   PubMed Web of Science ®Google Scholar
• Miyake T, Miyaoka H, Abe M et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol. Res.36, 139–142 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral center. J. Hepatol.45, 575–583 (2006).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging25, 219–239 (2008).
   PubMed Web of Science ®Google Scholar
• Lebovics E, Schaffner F, Klion EM, Simon C. Autoimmune chronic active hepatitis in postmenopausal women. Dig. Dis. Sci.30, 824–828 (1985).
   PubMed Web of Science ®Google Scholar
• Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology97, 1288–1293 (1989).
   PubMed Web of Science ®Google Scholar
• Heneghan MA, Norris SM, O’Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut48, 97–102 (2001).
   PubMed Web of Science ®Google Scholar
• Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist’s dilemma. Semin. Arthritis Rheum.35, 49–56 (2005).
   PubMed Web of Science ®Google Scholar
• Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am. J. Gastroenterol.101, 556–560 (2006).
   PubMed Web of Science ®Google Scholar
• Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann. Hepatol.5, 187–189 (2006).
   PubMedGoogle Scholar
• Werner M, Bjornsson E, Prytz H et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand. J. Gastroenterol.42, 986–91 (2007).
   PubMed Web of Science ®Google Scholar
• Varma RR, Michelsohn NH, Borkowf HI, Lewis JD. Pregnancy in cirrhotic and noncirrhotic portal hypertension. Obstet. Gynecol.50, 217–222 (1977).
   PubMed Web of Science ®Google Scholar
• Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am. J. Obstet. Gynecol.97, 387–394 (1967).
   PubMed Web of Science ®Google Scholar
• De Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am. J. Gastroenterol.101, 1390–1392 (2006).
   PubMed Web of Science ®Google Scholar
• Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am. J. Gastroenterol.97, 3160–3165 (2002).
   PubMed Web of Science ®Google Scholar
• Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science283, 1277–1278 (1999).
   PubMed Web of Science ®Google Scholar
• Baeres M, Herkel J, Czaja AJ et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut51, 259–264 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Autoantibodies in autoimmune liver disease. Adv. Clin. Chem.40, 127–164 (2005).
   PubMed Web of Science ®Google Scholar
• Ma Y, Okamoto M, Thomas MG et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology35, 658–664 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am. J. Gastroenterol.97, 413–419 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity35, 475–483 (2002).
   PubMed Web of Science ®Google Scholar
• Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J. Ped. Gastroenterol. Nutr.11, 138–140 (1990).
   PubMed Web of Science ®Google Scholar
• Maggiore G, Porta G, Bernard O et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J. Pediatr.116, 280–282 (1990).
   PubMed Web of Science ®Google Scholar
• Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J. Hepatol.27, 578–582 (1997).
   PubMed Web of Science ®Google Scholar
• Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin. Gastroenterol. Hepatol.2, 625–631 (2004).
   PubMed Web of Science ®Google Scholar
• Miyake Y, Iwasaki Y, Terada R et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment. Pharmacol. Ther.23, 1347–1353 (2006).
   PubMed Web of Science ®Google Scholar
• Viruet EJ, Torres EA. Steroid treatment in fulminant hepatic failure secondary to autoimmune hepatitis. P. R. Health Sci. J.17, 297–300 (1998).
   PubMedGoogle Scholar
• Ichai P, Duclos-Vallee J-C, Guettier C et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl.13, 996–1003 (2007).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology95, 448–453 (1988).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation (editorial). Liver Transpl.13, 953–955 (2007).
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Saeian K, Varma RR et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn’s disease compared with autoimmune hepatitis: a tertiary referral center experience. Am. J. Gastroenterol.100, 1121–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Penn I. Tumor incidence in human allograft recipients. Transplant. Proc.11, 1047–1051 (1979).
   PubMed Web of Science ®Google Scholar
• Wang KK, Czaja AJ, Beaver SJ, Go VLW. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology10, 39–43 (1989).
   PubMed Web of Science ®Google Scholar
• Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid resistant, autoimmune chronic active hepatitis. J. Clin. Gastroenterol.17, 317–320 (1993).
   PubMed Web of Science ®Google Scholar
• Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J. Hepatol.21, 1040–1047 (1994).
   PubMed Web of Science ®Google Scholar
• Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am. J. Gastroenterol.94, 241–248 (1999).
   PubMed Web of Science ®Google Scholar
• Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig. Dis. Sci.46, 1321–1327 (2001).
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Wright H, Carroll P et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am. J. Gastroenterol.90, 771–776 (1995).
   PubMed Web of Science ®Google Scholar
• Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J. Clin. Gastroenterol.38, 805–809 (2004).
   PubMed Web of Science ®Google Scholar
• Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol.13, 3232–3236 (2007).
   PubMed Web of Science ®Google Scholar
• Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology110, 271–274 (1996).
   PubMed Web of Science ®Google Scholar
• Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J. Hepatol.33, 371–375 (2000).
   PubMed Web of Science ®Google Scholar
• Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can. J. Gastroenterol.18, 321–326 (2004).
   PubMed Web of Science ®Google Scholar
• Chatur N, Ramji A, Bain VG et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int.25, 723–727 (2005).
   PubMed Web of Science ®Google Scholar
• Inductivo-Yu I, Adams A, Gish RG et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin. Gastroenterol. Hepatol.5, 799–802 (2007).
   PubMed Web of Science ®Google Scholar
• Hlivko JT, Shiffman ML, Stravitz RT et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin. Gastroenterol. Hepatol.6, 1036–1040 (2008).
   PubMed Web of Science ®Google Scholar
• Hennes EM, Oo YH, Schramm C et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am. J. Gastroenterol.103, 3063–3070 (2008).
   PubMed Web of Science ®Google Scholar
• Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig. Dis. Sci. DOI: 10.1007/s10620-008-0632-0 (Epub ahead of print).
   Google Scholar
• Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin. Pharmacother.7, 145–156 (2006).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree (editorial). J. Hepatol. (2009) (Epub ahead of print).
   Google Scholar
• Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs28, 485–518 (1984).
   PubMed Web of Science ®Google Scholar
• Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther.8, 585–590 (1994).
   PubMed Web of Science ®Google Scholar
• Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J. Gastroenterol.9, 2681–2685 (2003).
   PubMed Web of Science ®Google Scholar
• Wiegand J, Schuller A, Kanzler S et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int.25, 927–934 (2005).
   PubMed Web of Science ®Google Scholar
• Zandieh I, Krygier D, Wong V et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can. J. Gastroenterol.22, 388–392 (2008).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology119, 1312–1316 (2000).
   PubMed Web of Science ®Google Scholar
• Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis – report of three cases. Z. Gastroenterol.35, 571–578 (1997).
   PubMed Web of Science ®Google Scholar
• Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J. Hepatol.29, 990–993 (1998).
   PubMed Web of Science ®Google Scholar
• Kerkar N, Dugan C, Rumbo C et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J. Transplant.5, 1085–1089 (2005).
   PubMed Web of Science ®Google Scholar
• Santos ES, Arosemena LR, Raez LE, O’Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int.26, 625–629 (2006).
   PubMed Web of Science ®Google Scholar
• Carmassi F, Morale R, Puccetti R et al. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin. Exp. Rheumatol.10, 13–17 (1992).
   PubMedGoogle Scholar
• Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A et al. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis. Rev. Esp. Enferm. Dig.91, 630–638 (1999).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yoneda M, Yokohama S et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol.13, 490–495 (1998).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology30, 1381–1386 (1999).
   PubMed Web of Science ®Google Scholar
• de Boer NKH, van Nieuwkerk CMJ, Pages MNA, de Boer SY, Derijks LJJ, Mulder CJJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur. J. Gastroenterol.17, 457–461 (2005).
   PubMed Web of Science ®Google Scholar
• de Boer NKH, De Graaf P, Wilhelm AJ, Mulder CJJ, Van Bodegraven AA. On the limitation of 6-thioguaninenucleotide monitoring during thioguanine treatment. Aliment. Pharmacol. Ther.22, 447–451 (2005).
   PubMed Web of Science ®Google Scholar
• Chase WF, Winn RE, Mayes GR. Oral pulse prednisone therapy in the treatment of HBsAg negative chronic active hepatitis. Gastroenterology83, 1292–1296 (1982).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Wang KK, Shiels MT, Katzmann JA. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J. Hepatol.17, 180–186 (1993).
   PubMed Web of Science ®Google Scholar
• Cross TJS, Antoniades CG, Muieson P et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl.13, 1382–1388 (2007).
   PubMed Web of Science ®Google Scholar
• Ahmed M, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transpl. Proc.29, 496 (1997).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Samuel D, Sebagh M et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J. Hepatol.30, 131–141 (1999).
   PubMed Web of Science ®Google Scholar
• Reich DJ, Fiel I, Guarrera JV et al. Liver transplantation for autoimmune hepatitis. Hepatology32, 693–700 (2000).
   PubMed Web of Science ®Google Scholar
• Neuberger J. Transplantation for autoimmune hepatitis. Semin. Liver Dis.22, 379–385 (2002).
   PubMed Web of Science ®Google Scholar
• Vogel A, Heinrich E, Bahr MJ et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin. Transplant.18, 62–69 (2004).
   PubMed Web of Science ®Google Scholar
• Khalaf H, Mourad W, El-Sheikh Y et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant. Proc.39, 1166–1170 (2007).
   PubMed Web of Science ®Google Scholar
• Campsen J, Zimmerman MA, Trotter JF et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl.14, 1281–1286 (2008).
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Demetris AJ, Belle SH et al. Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology28, 638–645 (1998).
   PubMed Web of Science ®Google Scholar
• Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS liver transplant registry. In: Clinical Transplants 1998. Cecka JM, Terasaki PI (Eds). UCLA Tissue Typing Laboratories, CA, USA, 17–37 (1999).
   Google Scholar
• Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation37, 363–365 (1984).
   PubMed Web of Science ®Google Scholar
• Devlin J, Donaldson P, Portmann B, Heaton N, Tan K-C, Williams R. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl. Surg.1, 162–165 (1995).
   PubMedGoogle Scholar
• Gotz G, Neuhaus R, Bechstein WO et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant. Proc.31, 430–431 (1999).
   PubMed Web of Science ®Google Scholar
• Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation68, 253–256 (1999).
   PubMed Web of Science ®Google Scholar
• Gonazalez-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl.7, 302–310 (2001).
   PubMed Web of Science ®Google Scholar
• Kerkar N, Hadzic N, Davies ET et al.De-novo autoimmune hepatitis after liver transplantation. Lancet351, 409–413 (1998).
   PubMed Web of Science ®Google Scholar
• Jones DEJ, James OFW, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology30, 53–57 (1999).
   PubMed Web of Science ®Google Scholar
• Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology. A rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation71, 664–668 (2001).
   PubMed Web of Science ®Google Scholar
• Heneghan MA, Portmann BC, Norris SM et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology34, 464–470 (2001).
   PubMed Web of Science ®Google Scholar
• Spada M, Bertani A, Sonzogni A et al. A cause of late graft dysfunction after liver transplantation in children: de novo autoimmune hepatitis. Transplant. Proc.33, 1747–1748 (2001).
   PubMed Web of Science ®Google Scholar
• Salcedo M, Vaquero J, Banares R et al. Response to steroids in de novo autoimmune hepatitis after transplantation. Hepatology35, 349–356 (2002).
   PubMed Web of Science ®Google Scholar
• Keaveny AP, Gordon FD, Khettry U. Post-liver transplantation de novo hepatitis with overlap features. Pathol. Int.55, 660–664 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC et al.De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant. Proc.38, 1467–1470 (2006).
   PubMed Web of Science ®Google Scholar
• Huguet S, Vinh J, Johanet C et al. Identification by proteomic tool of atypical anti-liver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. Ann. NY Acad. Sci.1109, 345–357 (2007).
   PubMed Web of Science ®Google Scholar
• Venick RS, McDiarmid SV, Farmer DG et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am. J. Transpl.7, 955–963 (2007).
   PubMed Web of Science ®Google Scholar
• Lefkowitch JH. Diagnostic issues in transplantation pathology. Clin. Liver Dis.6, 555–570 (2002).
   PubMedGoogle Scholar
• Demetris AJ, Adeyi O, Bellamy CO et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology44, 489–501 (2006).
   PubMed Web of Science ®Google Scholar
• Fiel MI, Agarwal K, Stanca C et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl.14, 861–871 (2008).
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? (editorial). Liver Transpl.14, 750–755 (2008).
   PubMed Web of Science ®Google Scholar
• Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl.14, 625–632 (2008).
   PubMed Web of Science ®Google Scholar
• Hayashi M, Keefe EB, Krams SM et al. Allograft rejection after liver transplantation for autoimmune liver disease. Liver Transplant. Surg.4, 208–214 (1998).
   PubMedGoogle Scholar
• Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid dependent after liver transplantation? (editorial). Liver Transplant. Surg.5, 460–463 (1999).
   PubMedGoogle Scholar
• Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl. Surg.5, 375–380 (1999).
   PubMedGoogle Scholar
• Czaja AJ. Autoimmune hepatitis – part A: pathogenesis. Expert Rev. Gastroenterol. Hepatol.1(1), 113–128 (2007).
   PubMedGoogle Scholar
• Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology39, 1066–1074 (2004).
   PubMed Web of Science ®Google Scholar
• Christen U, Holdener M, Hintermann E. Animal models of autoimmune hepatitis. Autoimmun. Rev.6, 306–311 (2007).
   PubMed Web of Science ®Google Scholar
• Holdener M, Hintermann E, Bayer M et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med.205, 1409–1422 (2008).
   PubMed Web of Science ®Google Scholar
• Bowen DG. Of mice and molecular mimicry: modeling autoimmune hepatitis. Hepatology48, 1013–1015 (2008).
   PubMedGoogle Scholar
• Kyriakou DS, Alexandrakis MG, Zachou K, Passam F, Stathakis NE, Dalekos GN. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J. Hepatol.39, 679–685 (2003).
   PubMed Web of Science ®Google Scholar
• Tsikrikoni A, Kyriakou DS, Rigopoulou EI et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J. Hepatol.42, 393–399 (2005).
   PubMed Web of Science ®Google Scholar
• Zachou K, Rigopoulou EI, Tsikrikoni A et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J. Autoimmun.25, 283–288 (2005).
   PubMed Web of Science ®Google Scholar
• Tsikrikoni A, Rigopoulou EI, Zachou K, Liaskos C, Kyriakou D, Dalekos GN. Bone marrow findings in patients with autoimmune liver diseases. J. Gastroenterol. Hepatol.23(8 Pt 2), e416–e421 (2008).
   Web of Science ®Google Scholar
• Kuo TK, Hung S-P, Chuang C-H et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology134, 2111–2121 (2008).
   PubMed Web of Science ®Google Scholar
• Longhi MS, Ma Y, Mitry RR et al. Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J. Autoimmun.25, 63–71 (2005).
   PubMed Web of Science ®Google Scholar
• Longhi MS, Hussain MJ, Mitry RR et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J. Immunol.176, 4484–4491 (2006).
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Heathcote J. T regulatory cells and autoimmune liver disease (editorial). Liver Int.28, 155–157 (2008).
   PubMed Web of Science ®Google Scholar
• Longhi MS, Meda F, Wang P et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology47, 581–591 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot study of interferon nonresponders. Gastroenterology118, 655–660 (2000).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology119, 1461–1472 (2000).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117, 761–769 (1999).
   PubMed Web of Science ®Google Scholar
• Naveau S, Chollet-Martin S, Dharancy S et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology39, 1390–1397 (2004).
   PubMed Web of Science ®Google Scholar
• Boetticher NC, Peine CJ, Kwo P et al. A randomized, double-blinded, placebo-controlled mulicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology135, 1953–1960 (2008).
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Canas C, Jaller J-J, Restrepo J-C, Anaya J-M. Serious liver disease induced by infliximab. Clin. Rheumatol.26, 578–581 (2007).
   PubMed Web of Science ®Google Scholar
• Geramno V, Picchianti Diamanti A, Baccano G et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann. Rheum. Dis.64, 1519–1520 (2005).
   PubMed Web of Science ®Google Scholar
• Hannon GJ. RNA interference. Nature418, 244–251 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson BL. Hepatic diseases – hitting the target with inhibitory RNAs. N. Engl. J. Med.349, 2357–2359 (2003).
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature431, 371–378 (2004).
   PubMed Web of Science ®Google Scholar
• McCafferty AP, Nakai H, Pandey K et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol.21, 639–644 (2003).
   PubMed Web of Science ®Google Scholar
• Song E, Lee S-K, Wang J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med.9, 347–351 (2003).
   PubMed Web of Science ®Google Scholar
• Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc. Natl. Acad. Sci. USA95, 12528–12531 (1998).
   PubMed Web of Science ®Google Scholar
• Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum. Immunol.61, 640–650 (2000).
   PubMed Web of Science ®Google Scholar
• Schwartz RS. The new immunology – the end of immunosuppressive drug therapy (editorial)? N. Engl. J. Med.340, 1754–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Guinan EC, Boussiotis VA, Neuberg D et al. Transplantation of anergic histoincompatible bone marrow allografts. N. Eng. J. Med.340, 1704–1714 (1999).
   PubMed Web of Science ®Google Scholar
• Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm. Res.48, 106–119 (1999).
   PubMed Web of Science ®Google Scholar
• Nagler A, Pines M, Abadi U et al. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology31, 641–648 (2000).
   PubMed Web of Science ®Google Scholar
• Lohse AW, Dienes HP, Meyer zum Buschenfelde K-H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology27, 1536–1543 (1998).
   PubMed Web of Science ®Google Scholar